Home > Insider Trading > Filing (0001209191-21-009455)

Filing Details

Accession Number:: 0001209191-21-009455
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-02-10 19:40:18
Reporting Period:: 2021-02-08

Accepted Time:: 2021-02-10 19:40:18
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1714899	Denali Therapeutics Inc.	DNLI	Biological Products, (No Disgnostic Substances) (2836)	463872213

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1724310	J. Ryan Watts	C/O Denali Therapeutics Inc. 161 Oyster Point Blvd. South San Francisco CA 94080	President And Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2021-02-08	5,516	$0.00	2,310,165	No	4	M	Indirect	See footnote
Common Stock	Acquisiton	2021-02-08	8,800	$0.00	2,318,965	No	4	M	Indirect	See footnote
Common Stock	Disposition	2021-02-09	2,667	$73.24	2,316,298	No	4	S	Indirect	See footnote
Common Stock	Disposition	2021-02-09	1,634	$74.05	2,314,664	No	4	S	Indirect	See footnote
Common Stock	Disposition	2021-02-09	811	$75.07	2,313,853	No	4	S	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Indirect	See footnote
No	4	M	Indirect	See footnote
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Units	Disposition	2021-02-08	5,516	$0.00	5,516	$0.00
Common Stock	Restricted Stock Units	Disposition	2021-02-08	8,800	$0.00	8,800	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	M	Direct
17,600			No	4	M	Direct

Footnotes

Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer.
The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee.
Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units.
The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $72.61 to $73.58 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $73.62 to $74.50 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $74.79 to $75.195 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
50% of the restricted stock units vested on February 8, 2020 and the remaining 50% of the restricted stock units vested on February 8, 2021, subject to the Reporting Person remaining a service provider of the Issuer through each such date.
25% of the restricted stock units vested on February 8, 2020 (the "Vesting Commencement Date") and an additional 25% of the restricted stock units shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date.